The findings support extended anticoagulation in patients with active, ongoing cancer and isolated distal DVT, with caveats, including the need for individualized patient treatment decisions.
No significant differences in nondiagnostic results or hematomas seen when the blood thinners are continued, while discontinuing the medications may have risks.
New evidence points to the prognostic value of cardiac troponin T in identifying myocardial injury and subsequent mortality risk after cardiac surgery.
The quest for an anticoagulant that can prevent cardiovascular events without bleeding is something of a holy grail in cardiovascular medicine. Could factor XI inhibitors be the long-sought answer?